Literature DB >> 24604766

Altered RIG-I/DDX58-mediated innate immunity in dermatomyositis.

Xavier Suárez-Calvet1, Eduard Gallardo, Gisela Nogales-Gadea, Luis Querol, Miquel Navas, Jordi Díaz-Manera, Ricard Rojas-Garcia, Isabel Illa.   

Abstract

We investigated the molecular mechanisms involved in the pathogenesis of three inflammatory myopathies, dermatomyositis (DM), polymyositis (PM) and inclusion body myositis (IBM). We performed microarray experiments(†) using microdissected pathological muscle fibres from 15 patients with these disorders and five controls. Differentially expressed candidate genes were validated by immunohistochemistry on muscle biopsies, and the altered pathways were analysed in human myotube cultures. Up-regulation of genes involved in viral and nucleic acid recognition were found in the three myopathies but not in controls. In DM, retinoic acid-inducible gene 1 (RIG-I, DDX58) and the novel antiviral factor DDX60, which promotes RIG-I-mediated signalling, were significantly up-regulated, followed by IFIH1 (MDA5) and TLR3. Immunohistochemistry confirmed over-expression of RIG-I in pathological muscle fibres in 5/5 DM, 0/5 PM and 0/5 IBM patients, and in 0/5 controls. Stimulation of human myotubes with a ligand of RIG-I produced a significant secretion of interferon-β (IFNβ; p < 0.05) and up-regulation of class I MHC, RIG-I and TLR3 (p < 0.05) by IFNβ-dependent and TLR3-independent mechanisms. RIG-I-mediated innate immunity, triggered by a viral or damage signal, plays a significant role in the pathogenesis of DM, but not in that of PM or IBM.
Copyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  DDX58; RIG-I; dermatomyositis; inflammatory myopathy; innate immunity

Mesh:

Substances:

Year:  2014        PMID: 24604766     DOI: 10.1002/path.4346

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  35 in total

Review 1.  Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment.

Authors:  Jian-Qiang Wu; Mei-Ping Lu; Ann M Reed
Journal:  World J Pediatr       Date:  2019-09-26       Impact factor: 2.764

2.  Vascular changes and perifascicular muscle fiber damage in dermatomyositis: another question of the chicken or the egg that is on our mind.

Authors:  Boel De Paepe
Journal:  Ann Transl Med       Date:  2017-01

3.  Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy.

Authors:  Manish Suneja; Daniel K Fox; Brian D Fink; Judy A Herlein; Christopher M Adams; William I Sivitz
Journal:  Transl Res       Date:  2015-01-28       Impact factor: 7.012

4.  Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs.

Authors:  Ruxue Yin; Gangjian Wang; Lei Zhang; Tianfang Li; Shengyun Liu
Journal:  Clin Rheumatol       Date:  2021-01-03       Impact factor: 2.980

5.  Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses.

Authors:  Ruoyi Jiang; Miriam L Fichtner; Kenneth B Hoehn; Minh C Pham; Panos Stathopoulos; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  JCI Insight       Date:  2020-07-23

Review 6.  Treatment of Juvenile Dermatomyositis: An Update.

Authors:  Charalampia Papadopoulou; Lucy R Wedderburn
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

Review 7.  Autoimmune Myopathies: Updates on Evaluation and Treatment.

Authors:  Emer R McGrath; Christopher T Doughty; Anthony A Amato
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 8.  Updates on the Immunopathology in Idiopathic Inflammatory Myopathies.

Authors:  Akinori Uruha; Hans-Hilmar Goebel; Werner Stenzel
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

9.  213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Authors:  Olivier Benveniste; Lisa G Rider
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

Review 10.  The influence of interferon on healthy and diseased skin.

Authors:  Grace A Hile; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  Cytokine       Date:  2018-12-06       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.